个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Icaritin with autophagy/mitophagy inhibitors synergistically enhances anticancer efficacy and apoptotic effects through PINK1/Parkin-mediated mitophagy in hepatocellular carcinoma

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Luo Piao[1,2,3] ; An Yehai[1] ; He Jingqian[8] ; Xing Xuefeng[1] ; Zhang Qian[1,2] ; Liu Xueying[3] ; Chen Yu[1] ; Yuan Haitao[3] ; Chen Junhui[3] ; Wong Yin-Kwan[3] ; Huang Jingnan[3] ; Gong Zipeng[9] ; Du Qingfeng[1] ; Xiao Wei[1,7] ; Wang Jigang[1,2,3,4,5,6] ;
机构： [1]School of Traditional Chinese Medicine and School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, Guangdong, China [2]State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China [3]Department of Pulmonary and Critical Care Medicine, Shenzhen Institute of Respiratory Diseases, and Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital, First Affiliated Hospital of Southern University of Science and Technology, Second Clinical Medical College of Jinan University, Shenzhen, 518020, Guangdong, China. [4]State Key Laboratory of Antiviral Drugs, School of Pharmacy, Henan University, Kaifeng, 475004, China [5]Henan University, N. Jinming Ave, Kaifeng, 475004, Henan, China [6]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. [7]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangdong Pharmaceutical University, Guangzhou, 510006, China. [8]The Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. . [9]Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou University of Chinese Medicine, Guiyang, 550001, China.
出处：
DOI： 10.1016/j.canlet.2024.216621
ISSN：

关键词： Icaritin hepatocellular carcinoma mitophagy apoptosis PINK1-Parkin

摘要：
Hepatocellular carcinoma (HCC) is among the deadliest malignancies worldwide and still a pressing clinical problem. Icaritin, a natural compound obtained from the Epimedium genus plant, has garnered significant attention as a potential therapeutic drug for HCC therapies. Mitophagy plays a crucial role in mitochondrial quality control through efficiently eliminating damaged mitochondria. However, the specific mechanisms of the interplay between mitophagy and apoptosis in HCC is still unclear. We aimed to explore the cross-talk between icaritin-induced mitophagy and apoptosis in HCC cells and investigate its potential mechanisms. Firstly, we confirmed that icaritin inhibits proliferation and migration while inducing mitochondrial damage and reactive oxygen species (ROS) production in HCC cells. Secondly, based on proteomics analysis, we discovered that icaritin inhibits the growth of tumor cells and disrupts their mitochondrial homeostasis through the regulation of both mitophagy and apoptosis. Thirdly, icaritin causes mitophagy mediated by PINK1-Parkin signaling via regulating feedforward loop. Furthermore, knockdown of PINK1/Parkin leads to inhibition of mitophagy, which promotes cell death induced by icaritin in HCC cells. Finally, autophagy/mitophagy inhibitors remarkably enhance icaritin-induced cell death and anticancer efficacy. Collectively, our findings reveal that icaritin suppresses growth, proliferation and migration of HCC cell through induction of mitophagy and apoptosis, while inhibition of mitophagy significantly increased the anti-cancer and pro-apoptotic effects of icaritin, indicating that targeting autophagy or mitophagy is a novel approach to overcome drug resistance and enhance anticancer therapies.Copyright © 2024. Published by Elsevier B.V.

基金：
The study is financially supported by National Key Research and Development Program of China (2022YFC2303600 and 2020YFA0908000); the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (No: ZYYCXTD-C-202002); the National Natural Science Foundation of China (82141001, 82274182, 82074098); the CACMS Innovation Fund (CI2023E002, CI2021A05101 and CI2021A05104); the Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (CI2021B014); the Science and Technology Foundation of Shenzhen (JCYJ20210324115800001); the Science and Technology Foundation of Shenzhen (Shenzhen Clinical Medical Research Center for Geriatric Diseases); The Shenzhen Medical Research Fund of Shenzhen Medical Academy of Research and Translation(B2302051); support from State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs; the Distinguished Expert Project of Sichuan Province Tianfu Scholar(CW202002); the Fundamental Research Funds for the Central public welfare research institutes(ZZ13-ZD-07), the Shenzhen Governmental Sustainable Development Fund (KCXFZ20201221173612034), Scientific and technological innovation project of China Academy of Chinese Medical Sciences(CI2023D003).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]School of Traditional Chinese Medicine and School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, Guangdong, China [2]State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China [3]Department of Pulmonary and Critical Care Medicine, Shenzhen Institute of Respiratory Diseases, and Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital, First Affiliated Hospital of Southern University of Science and Technology, Second Clinical Medical College of Jinan University, Shenzhen, 518020, Guangdong, China.
共同第一作者：
通讯作者：
通讯机构： [1]School of Traditional Chinese Medicine and School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, Guangdong, China [2]State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China [3]Department of Pulmonary and Critical Care Medicine, Shenzhen Institute of Respiratory Diseases, and Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital, First Affiliated Hospital of Southern University of Science and Technology, Second Clinical Medical College of Jinan University, Shenzhen, 518020, Guangdong, China. [4]State Key Laboratory of Antiviral Drugs, School of Pharmacy, Henan University, Kaifeng, 475004, China [5]Henan University, N. Jinming Ave, Kaifeng, 475004, Henan, China [6]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. [7]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
推荐引用方式(GB/T 7714)：
Luo Piao,An Yehai,He Jingqian,et al.Icaritin with autophagy/mitophagy inhibitors synergistically enhances anticancer efficacy and apoptotic effects through PINK1/Parkin-mediated mitophagy in hepatocellular carcinoma[J].CANCER LETTERS.2024,587:216621.doi:10.1016/j.canlet.2024.216621.
APA：
Luo Piao,An Yehai,He Jingqian,Xing Xuefeng,Zhang Qian...&Wang Jigang.(2024).Icaritin with autophagy/mitophagy inhibitors synergistically enhances anticancer efficacy and apoptotic effects through PINK1/Parkin-mediated mitophagy in hepatocellular carcinoma.CANCER LETTERS,587,
MLA：
Luo Piao,et al."Icaritin with autophagy/mitophagy inhibitors synergistically enhances anticancer efficacy and apoptotic effects through PINK1/Parkin-mediated mitophagy in hepatocellular carcinoma".CANCER LETTERS 587.(2024):216621

相关文献

[1]MicroRNA-1 promotes apoptosis of hepatocarcinoma cells by targeting apoptosis inhibitor-5 (API-5). [2]The antitumor effects of icaritin against breast cancer is related to estrogen receptors. [3]Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway. [4]SOX11 regulates apoptosis and cell cycle in hepatocellular carcinoma via Wnt/β-catenin signaling pathway. [5]Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma. [6]Sphingosine 1-phosphate regulates proliferation, cell cycle and apoptosis of hepatocellular carcinoma cells via syndecan-1. [7]NR0B1 augments sorafenib resistance in hepatocellular carcinoma through promoting autophagy and inhibiting apoptosis [8]Targeted polymeric therapeutic nanoparticles: Design and interactions with hepatocellular carcinoma. [9]NAD(P)H: Quinone oxidoreductase 1 overexpression in hepatocellular carcinoma potentiates apoptosis evasion through regulating stabilization of X-linked inhibitor of apoptosis protein. [10]Follistatin-like protein 5 inhibits hepatocellular carcinoma progression by inducing caspase-dependent apoptosis and regulating Bcl-2 family proteins.

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号